Insider · CIK 0001320873
Edward Neugeboren
Files at GRCE (Acasti Pharma Inc.), MTNB (Matinas BioPharma Holdings, Inc.). First filing -, latest -.
In brief
Edward Neugeboren files SEC Form 4 as director at GRCE (Acasti Pharma Inc.), and also at MTNB (Matinas BioPharma Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Edward Neugeboren has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +12,200 | $0.00 | $0 | 12,200 | 22 d ago |
| Jan 8, 2026 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| May 9, 2025 | GRCE Acasti Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| Apr 30, 2025 | MTNB Matinas BioPharma Holdings, Inc. | AGrant or award Stock Option (right to Buy)derivative | +11,600 | $0.00 | $0 | 11,600 | May 2, 2025 |
| Dec 19, 2023 | GRCE Acasti Pharma Inc. | AGrant or award Stock Options (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Dec 20, 2023 |
Questions about Edward Neugeboren
Answered from the filings on this page, as of the latest one.
Is Edward Neugeboren buying or selling?
Edward Neugeboren has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Edward Neugeboren's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Edward Neugeboren has 0.
Where does Edward Neugeboren file Form 4?
Edward Neugeboren has filed Form 4 at GRCE (Acasti Pharma Inc.); MTNB (Matinas BioPharma Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.